<DOC>
	<DOCNO>NCT00922311</DOCNO>
	<brief_summary>Study objective : To investigate potential anti-proteinuric efficacy aliskiren , novel direct renin inhibitor ( DRI ) , addition angiotensin receptor blocker ( ARB ) immunoglobulin A nephropathy ( IgAN ) patient risk develop progressive renal failure .</brief_summary>
	<brief_title>Aliskiren Proteinuric IgAN Despite Angiotensin Blockade</brief_title>
	<detailed_description>This open-label pilot study IgAN patient persistent proteinuria despite maximum dose ARB treatment assign receive Aliskiren . There optional addition anti-hypertensive agent achieve optimal target blood pressure &lt; 130/80 mmHg .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Male female 18 70 year age Histologic diagnosis IgA nephropathy Proteinuria &gt; 1 g/day UPC &gt; 1 mg/mg 113 mg/mmol least twice Receiving treatment maximum dose ARB least 3 month Patients willing give write , informed consent eGFR &lt; 15 ml/min/1.73 sq.m UPC &gt; 5000 mg/g 570 mg/mmol , &lt; 500 mg/g 57 mg/mmol Serum K+ &gt; 5.2 mmol/L Presence bilateral renal artery stenosis Presence diabetes mellitus Renal histology show pathology IgAN Known allergy ARB DRI Patients ARB/ACEi combination within 12 week randomization Concurrent treatment corticosteroid , Nsaid , immunosuppressant Patients connective tissue disease obstructive uropathy Patients malignancy condition severely limit life expectancy Female pregnant intend conceive Female childbearing age unwilling practice contraception Patients unable give inform consent Patients simultaneously participate another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Proteinuria</keyword>
</DOC>